- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00993785
CoStar Catheter System Evaluation (CONCISE)
October 27, 2009 updated by: Conor Medsystems
To evaluate product performance and safety of the Catheter Design for the treatment of a single coronary lesion.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Segeberger Kliniken GmbH
-
Am Kurpark 1, Segeberger Kliniken GmbH, Germany, 23795
- Herz-Kreislauf-Zentrum
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is ≥18 years of age.
- Eligible for percutaneous coronary intervention (PCI).
- Documented stable or unstable angina pectoris (Canadian Cardiovascular Society Classification [CCS] 1, 2, 3, or 4), documented ischemia, or documented silent ischemia.
- Left ventricular ejection fraction (LVEF) ≥25% documented within the last 6 weeks.
- Acceptable candidate for coronary artery bypass graft surgery (CABG).
- Patient understands the study requirements and the treatment procedures and provides written Informed Consent using a form that has been approved by the local Institutional Review Board or Ethics Committee before any study-specific tests or procedures are performed.
- Willing to comply with all specified follow-up evaluations.
Inclusion Criteria (Angiographic):
- A single de novo lesion per study subject may be treated with the study device.
- Each target lesion may be composed of multiple lesions but must be completely coverable by one (1) study stent.
- Cumulative target lesion length per vessel is ≤24 mm based on a visual estimate.
- RVD of ≥2.5 mm to ≤3.0 mm based on a visual estimate.
- Target lesion diameter stenosis ≥50% and <100% based on a visual estimate.
- Target vessel has not undergone prior revascularization within the preceding 6 months.
- Target lesion must be a minimum of 10 mm distance from any previously treated segment of the target vessel
Exclusion Criteria:
- Known sensitivity to cobalt chromium, paclitaxel or polymeric matrices: PLGA.
- Planned treatment with any other PCI device in the target vessel(s).
- Acute MI within 72 hours prior to the index procedure as defined by the presence of a new pathologic Q wave, or creatinine kinase (CK) >2 times the laboratory upper limits of normal and elevated MB.
- The patient is in cardiogenic shock.
- Cerebrovascular Accident (CVA) within the past 6 months.
- Acute or chronic renal dysfunction (creatinine >2.0 mg/dl or >150 µmol/L).
- Contraindication to ASA or to clopidogrel.
- Thrombocytopenia (platelet count <100, 000/mm3).
- Active gastrointestinal (GI) bleeding within the past three months.
- Any prior true anaphylactic reaction to contrast agents.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OTW Catheter System
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Study Completion (Actual)
April 1, 2008
Study Registration Dates
First Submitted
October 9, 2009
First Submitted That Met QC Criteria
October 9, 2009
First Posted (Estimate)
October 12, 2009
Study Record Updates
Last Update Posted (Estimate)
October 29, 2009
Last Update Submitted That Met QC Criteria
October 27, 2009
Last Verified
October 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symptomatic Ischemic Heart Disease
-
Cordis CorporationConor MedsystemsCompletedTreatment of Symptomatic Ischemic Heart DiseaseItaly
-
Boston Scientific CorporationCompletedSymptomatic Ischemic Saphenous Vein Graft DiseaseUnited States, Canada
-
Biotronik AGTerminatedRestenoses, Coronary | de Novo | Symptomatic Ischemic Heart DiseaseBrazil
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingIschemic Heart Disease | Hypotension SymptomaticTaiwan
-
Assaf-Harofeh Medical CenterCompletedChronic Ischemic Symptomatic Heart FailureIsrael
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, AkershusTerminatedSymptomatic Haemorrhoidal DiseaseNorway
-
Denver Health and Hospital AuthorityGeneral ElectricCompletedChest Pain | Symptomatic Ischemic EquivalentUnited States
-
Genzyme, a Sanofi CompanyTerminatedIschemic Heart Disease | Ischemic Cardiomyopathy | Ischemic Heart FailureBelgium, France, Germany, Italy, Switzerland, United Kingdom
-
Xijing HospitalUnknownSymptomatic Cervical Disc Disease
Clinical Trials on Costar Coronary Stent Delivery System
-
Cordis CorporationConor MedsystemsCompletedCoronary DiseaseUnited States
-
Conor MedsystemsTerminated
-
EndologixCompleted
-
Xlumena, Inc.Completed
-
Conor MedsystemsGetz PharmaTerminated
-
CCRF Consulting Co., Ltd.Peking University First Hospital; Terumo Medical(shanghai) Co.,Ltd.UnknownFree Rate of Cardiac or Cerebrovascular Events | Transradial-transfemoral Coronary Interventions ComparisonChina
-
Medinol Ltd.CompletedIschemic Heart DiseaseIsrael, Sweden, Belgium, Germany
-
Boston Scientific CorporationUnknown
-
Elixir Medical CorporationCompletedCoronary Artery DiseaseSwitzerland, New Zealand, Belgium, Poland, Australia, Brazil, Germany, Netherlands
-
CeloNova BioSciences, Inc.AlpinARCCompletedMyocardial Infarction | Stable Angina | Unstable Angina | STEMI | NSTEMI - Non-ST Segment Elevation MI | ACS - Acute Coronary SyndromeFrance